News

In August 2003, the US Department of Veterans Affairs (VA) awarded a contract for prostaglandin ophthalmic agents with travoprost as the agent of choice. Although there was no national mandate to switch patients from existing therapy, many VA facilities had agreements from their local ophthalmology and optometry departments to conduct a therapeutic interchange of patients from existing prostaglandins (eg, latanoprost) to travoprost.

Quality Models

Sure, the integrated delivery model produces good outcomes and lower costs, but it's not applicable everywhere, in spite of what politicians think

UnitedHealth's Dr. Reed Tuckson believes managing the health of large populations and individuals calls for the best in every stakeholder

Nearly two-thirds of plan sponsors say the economy is causing a shift toward placing greater accountability on members to manage their own health so plan dollars are spent more wisely